BRCA2 and ovarian carcinoma: As above, BRCA2, PTEN and CDH1 dominate these SL interactions (Fig. 2a) when all four cancers are taken together, whereas different genes dominate within the individual cancers – e.g. CDH1 (91 %) and PTEN (9 %) for breast, PTEN (88 %) and BRCA2 (9 %) for prostate, and CDH1 (58 %) and BRCA1 (38 %) for ovarian cancers.